Novetats

El Dr Masana i el seu equip publiquen els resultats del seu estudi al Clinical Trials

Qualitative and Quantitative Characterization of HDL in T2D After Fenofibrate or Niacin Treatment in Spanish Population

L'estudi "Characterization of High Density Lipoprotein (HDL) in Type 2 Diabetes (T2D) After Fenofibrate or Niacin Treatment" liderat pel Dr Masana del Grup Unitat de recerca en lípids i arteriosclerosi (URLA) i la Unitat vascular i del metabolisme (UVASMET), i en col·laboració amb el seu equip de l'Hospital Universitari Sant Joan de Reus i el CIBERDEM, han estat publicat al Clinical Trials del U.S. National Institutes of Health i U.S. Department of Health & Human Services

Purpose: The structural and functional alterations of high density lipoproteins (HDL) levels in type 2 diabetes (T2D) patients linked to hypertriglyceridemia, hyperglycemia, insulin resistance, inflammation and oxidation, play a major role in the increased macrovascular risk in these patients. An impaired function of the adipose tissue (AT) in T2D contributes to low HDL concentrations.

Objectives: 1) Quantitative and qualitative characterisation of HDL subclasses by ultracentrifugation, proteomic and metabolomic techniques. 2) To study the relationship between the HDL subclasses, preβ1 HDL and remnant HDL, and clinical determinants of arteriosclerosis. 3) Functional in vitro studies of the HDL subclasses determined in Objective 1. 4) To study the role of AT determining the low HDL levels. 5) To study the impact of HDL increasing drugs on HDL qualitative changes.

Consulta'l

Pujar